Andrew Ihor Korytko

This inventor holds 16 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 7 EPO patents. Top assignees: Eli Lilly and Company, Amazon Technologies, Inc., Amunix Operating Inc.. Active years: 2009-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew Ihor Korytko. Retrieved from https://idiyas.com/inventor/andrew-ihor-korytko

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 (Patent Applications = 3)

% Patents Active = 68.8

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 7 (Patent Applications = 7)

Average Co-Inventor Count = 4.1

ph-index = 9

Forward Citations = 252(Granted Patents)

Location History:

Seattle, WA (US) (2013)
Oceanside, CA (US) (2009 - 2024)

Company Filing History:

15 out of 4,509

Eli Lilly and Company

patents

1 out of 23,631

Amazon Technologies, Inc.

patents

1 out of 24

Amunix Operating Inc.

patents

where one patent can have more than one assignee

Years Active: 2009-2024

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12059452 - Fusion proteins (2024-08-13),

2. 11253574 - Fusion proteins and methods of use (2022-02-22),

3. 10913799 - Anti-RANKL antibodies and uses thereof (2021-02-09),

4. 10709766 - Fusion proteins (2020-07-14),

5. 10584174 - Anti-Dkk-1-anti-RANKL bispecific antibody compounds (2020-03-10),

6. 10035839 - Blood glucose lowering compound (2018-07-31),

7. 9855318 - Fusion proteins (2018-01-02),

8. 8429019 - System and method for scheduled delivery of shipments with multiple shipment carriers (2013-04-23),

9. 8257704 - Anti-sclerostin antibodies (2012-09-04),

10. 8066995 - Anti-myostatin antibodies (2011-11-29),

11. 7988970 - Methods of treatment comprising administering an anti-sclerostin antibody (2011-08-02),

12. 7968686 - Glucagon receptor antagonists (2011-06-28),

13. 7745583 - Anti-myostatin antibodies (2010-06-29),

14. 7744874 - Anti-sclerostin antibodies (2010-06-29),

15. 7635760 - Anti-myostatin antibodies (2009-12-22),

Title: **The Innovative Mind of Andrew Ihor Korytko: A Pioneer in Diabetes Treatment**

Introduction

Andrew Ihor Korytko, based in Oceanside, CA, is a skilled inventor known for his remarkable contributions to medical science, particularly in diabetes treatment. With a remarkable portfolio of 15 patents, Korytko stands at the forefront of innovation in biopharmaceutical research.

Latest Patents

Among his latest innovations are his patents related to fusion proteins. These fusion proteins comprise an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker. This invention aims to enhance diabetes management, providing an extended time action profile which is pivotal for maintaining basal glucose control for longer periods. Korytko’s work in this area represents a significant leap forward in the treatment of diabetes.

Career Highlights

Throughout his influential career, Korytko has worked with prestigious companies in the pharmaceutical industry, including Eli Lilly and Company and Amunix Operating Inc. His experience in these organizations has allowed him to refine his expertise and contribute to substantial advancements in therapeutic developments.

Collaborations

Korytko’s innovative journey is marked by collaboration with notable colleagues such as David Bruce Baldwin and Pamela Jean Mitchell. These professional partnerships underscore the collaborative essence of scientific innovation, fostering an environment where groundbreaking ideas can thrive.

Conclusion

In conclusion, Andrew Ihor Korytko exemplifies the spirit of innovation in the medical field through his patents and collaborations aimed at improving diabetes treatment. His contributions continue to inspire and pave the way for future advancements in the realm of biopharmaceuticals.

Profile summary based on public USPTO records.